Compare
60 Degrees Pharmaceuticals, Inc. vs China SXT Pharmaceuticals, Inc. vs Northwest Biotherapeutics Inc vs BioXcel Therapeutics, Inc.
| Latest fiscal year | 60 Degrees Pharmaceuticals, Inc. SXTP | China SXT Pharmaceuticals, Inc. SXTC | Northwest Biotherapeutics Inc NWBO | BioXcel Therapeutics, Inc. BTAIQ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.01M | $1.14M | $1.38M | $642.0K |
| Revenue growth (YoY) | +65.5% | -34.6% | -0.3% | -71.7% |
| Gross margin | 22.3% | 21.9% | n/a | 74.5% (computed) |
| Operating margin | -771.6% | -625.9% | n/m | n/m |
| Net margin | -732.5% | -545.2% | n/m | n/m |
| Net income | -$7.37M | -$6.21M | -$60.16M | -$69.90M |
| EPS (Diluted) | -$11.73 | -$9.13 | -$0.04 | -$5.73 |
| Operating cash flow | -$6.85M | -$4.02M | -$44.76M | -$57.62M |
| Free cash flow | -$6.99M | n/a | -$46.27M | -$57.62M |
| Cash & equivalents | $1.51M | $28.18M | $3.04M | $28.41M |
| Total assets | $5.37M | $34.75M | $81.29M | $44.92M |
| Total liabilities | $1.99M | $5.05M | $128.86M | $140.38M |
| Shareholders' equity | $3.46M | $29.71M | -$60.28M | -$95.46M |
| Return on year-end equity | -212.7% | -20.9% | n/a | n/a |
| Shares outstanding | 1.16M | n/a | 1.56B | 22.33M |
Revenue, most recent five fiscal years
| Fiscal year | 60 Degrees Pharmaceuticals, Inc. | China SXT Pharmaceuticals, Inc. | Northwest Biotherapeutics Inc | BioXcel Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.01M Ended 2025-12-31 | $1.14M Ended 2026-03-31 | $1.38M Ended 2025-12-31 | $642.0K Ended 2025-12-31 |
| 1 year earlier | $607.6K Ended 2024-12-31 | $1.74M Ended 2025-03-31 | $1.38M Ended 2024-12-31 | $2.27M Ended 2024-12-31 |
| 2 years earlier | $253.6K Ended 2023-12-31 | $1.93M Ended 2024-03-31 | $1.93M Ended 2023-12-31 | $1.38M Ended 2023-12-31 |
| 3 years earlier | $223.2K Ended 2022-12-31 | $1.97M Ended 2023-03-31 | $1.68M Ended 2022-12-31 | $375.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $2.60M Ended 2022-03-31 | $1.00M Ended 2021-12-31 | n/a |